Barrett’s Esophagus: Understanding Risk and Prevention
At a Glance
Barrett's esophagus is a precancerous condition caused by chronic acid reflux, but the risk of it progressing to esophageal cancer is very low. Regular screening is for high-risk individuals, and abnormal cell changes can be safely treated during a standard endoscopy to prevent cancer.
For many people with chronic reflux, the greatest fear is that it will lead to cancer. While there is a link between long-term GERD and a condition called Barrett’s Esophagus, it is important to understand that the risk for any single individual remains remarkably low. Barrett’s is a condition where the body, in an attempt to protect itself from chronic acid injury, replaces the normal lining of the esophagus with a tougher, intestinal-like tissue [1].
Who Needs Screening?
Not everyone with heartburn needs to be screened for Barrett’s. Medical guidelines from the ACG and AGA recommend screening only for those at the highest risk. Usually, this means people who have had chronic GERD symptoms for at least 5 years AND have at least three of the following risk factors [2][3]:
- Age: Over 50 years old.
- Sex: Male.
- Race: Non-Hispanic White.
- Lifestyle: A current or past history of smoking.
- Body Type: Central obesity (carrying extra weight around the midsection).
- Family History: A first-degree relative (parent or sibling) with Barrett’s or esophageal cancer.
Understanding the Risk
If you are diagnosed with Barrett’s, it is a “precancerous” condition, but it is not cancer. The vast majority of people with Barrett’s will never develop esophageal cancer.
- Low Progression Rate: For patients with non-dysplastic Barrett’s (meaning the cells look stable), the risk of progressing to cancer is only about 0.2% to 0.5% per year [4].
- Length Matters: The risk of progression is also linked to the length of the Barrett’s segment; segments longer than 3 cm generally carry a slightly higher risk than shorter segments [5][6].
Surveillance and Monitoring
If you have Barrett’s, your doctor will put you on a surveillance schedule. This involves a regular endoscopy with biopsies to “check in” on the cells.
- Non-dysplastic Barrett’s: The standard recommendation is an endoscopy every 3 to 5 years [7][8].
- Low-Grade Dysplasia: If the cells begin to show early “angry” changes (dysplasia), your doctor may recommend more frequent check-ups or treatment to prevent further progression [5].
Treatment Before Cancer
If the cells reach a point where they are considered high-risk (high-grade dysplasia), we no longer have to rely on major surgery. Modern endoscopic eradication therapies allow doctors to treat the area during a standard endoscopy [9]:
- Endoscopic Mucosal Resection (EMR): The doctor physically removes any visible bumps or abnormal areas [10].
- Radiofrequency Ablation (RFA): The doctor uses heat (radio waves) to “burn away” the thin layer of abnormal Barrett’s tissue, allowing healthy, normal tissue to grow back in its place [11][12].
These treatments are highly effective and have significantly reduced the need for more invasive surgeries [9]. For most patients, a diagnosis of Barrett’s is simply a signal to stay vigilant with regular monitoring.
Common questions in this guide
Who should be screened for Barrett's esophagus?
Does having Barrett's esophagus mean I will get cancer?
What does non-dysplastic Barrett's mean on my pathology report?
How often do I need an endoscopy if I have Barrett's esophagus?
What happens if my Barrett's esophagus gets worse?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Given my age, sex, and history of reflux, do I meet the official ACG criteria for Barrett's screening?
- 2.If I have Barrett's, was it described as 'non-dysplastic,' or were there signs of 'low-grade' or 'high-grade' dysplasia?
- 3.What is the length of my Barrett’s segment? Is it considered a 'short-segment' or 'long-segment,' and how does that affect my risk?
- 4.If my Barrett's is non-dysplastic, can we set a reminder for my next surveillance endoscopy in 3 to 5 years?
- 5.If dysplasia is found, am I a candidate for endoscopic treatments like radiofrequency ablation (RFA) instead of surgery?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
References
References (12)
- 1
Epidemiology of Barrett's Esophagus and Esophageal Carcinoma.
Fabian T, Leung A
The Surgical clinics of North America 2021; (101(3)):381-389 doi:10.1016/j.suc.2021.03.001.
PMID: 34048759 - 2
AGA Clinical Practice Update on New Technology and Innovation for Surveillance and Screening in Barrett's Esophagus: Expert Review.
Muthusamy VR, Wani S, Gyawali CP, et al.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2022; (20(12)):2696-2706.e1 doi:10.1016/j.cgh.2022.06.003.
PMID: 35788412 - 3
Endoscopic Screening for Barrett's Esophagus and Esophageal Adenocarcinoma: Rationale, Candidates, and Challenges.
Kamboj AK, Katzka DA, Iyer PG
Gastrointestinal endoscopy clinics of North America 2021; (31(1)):27-41 doi:10.1016/j.giec.2020.08.002.
PMID: 33213798 - 4
Diagnosis and Management of Barrett's Esophagus: An Updated ACG Guideline.
Shaheen NJ, Falk GW, Iyer PG, et al.
The American journal of gastroenterology 2022; (117(4)):559-587 doi:10.14309/ajg.0000000000001680.
PMID: 35354777 - 5
Barrett's esophagus surveillance in a prospective Dutch multi-center community-based cohort of 985 patients demonstrates low risk of neoplastic progression.
Klaver E, Bureo Gonzalez A, Mostafavi N, et al.
United European gastroenterology journal 2021; (9(8)):929-937 doi:10.1002/ueg2.12114.
PMID: 34228885 - 6
Should All Patients with Barrett's Esophagus Receive Ablation?
Shafa S, Carroll JE
Current gastroenterology reports 2023; (25(6)):115-121 doi:10.1007/s11894-023-00869-6.
PMID: 37204654 - 7
Barrett Esophagus: A Review.
Sharma P
JAMA 2022; (328(7)):663-671 doi:10.1001/jama.2022.13298.
PMID: 35972481 - 8
Evaluating Cost-Effectiveness of 85 Endoscopic Surveillance Strategies of Nondysplastic Barrett's Esophagus.
Vissapragada R, Bulamu NB, Yazbeck R, et al.
Journal of gastroenterology and hepatology 2026; (41(3)):992-1000 doi:10.1111/jgh.70238.
PMID: 41553019 - 9
The evolution of endoscopic therapy for Barrett's esophagus.
Condon A, Muthusamy VR
Therapeutic advances in gastrointestinal endoscopy 2021; (14()):26317745211051834 doi:10.1177/26317745211051834.
PMID: 34708204 - 10
Long-term durability of radiofrequency ablation for Barrett's-related neoplasia.
Haidry R, Lovat L
Current opinion in gastroenterology 2015; (31(4)):316-20 doi:10.1097/MOG.0000000000000190.
PMID: 26039723 - 11
Recurrent intestinal metaplasia at the gastroesophageal junction following endoscopic eradication of dysplastic Barrett's esophagus may not be benign.
Cameron GR, Desmond PV, Jayasekera CS, et al.
Endoscopy international open 2016; (4(8)):E849-58 doi:10.1055/s-0042-109608.
PMID: 27540572 - 12
Endoscopic therapy for Barrett's esophagus and early esophageal cancer: Where do we go from here?
Singh T, Sanaka MR, Thota PN
World journal of gastrointestinal endoscopy 2018; (10(9)):165-174 doi:10.4253/wjge.v10.i9.165.
PMID: 30283599
This information about Barrett's esophagus is for educational purposes only and does not replace medical advice. Always consult a gastroenterologist to discuss your specific screening needs and endoscopy results.
Get notified when new evidence is published on gastroesophageal reflux disease.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.